Granahan Investment Management LLC Sells 31,507 Shares of Natera, Inc. (NASDAQ:NTRA)

Granahan Investment Management LLC cut its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 36.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,442 shares of the medical research company's stock after selling 31,507 shares during the period. Granahan Investment Management LLC's holdings in Natera were worth $8,776,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. lifted its position in shares of Natera by 2.9% during the third quarter. Principal Financial Group Inc. now owns 1,012,498 shares of the medical research company's stock valued at $128,537,000 after purchasing an additional 28,751 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Natera by 49.1% during the 4th quarter. GAMMA Investing LLC now owns 641 shares of the medical research company's stock worth $101,000 after buying an additional 211 shares in the last quarter. Diversified Trust Co purchased a new position in shares of Natera in the 4th quarter worth approximately $220,000. Fulton Bank N.A. boosted its stake in shares of Natera by 3.8% in the 4th quarter. Fulton Bank N.A. now owns 3,581 shares of the medical research company's stock worth $567,000 after buying an additional 132 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in shares of Natera by 1.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 11,001 shares of the medical research company's stock valued at $1,741,000 after acquiring an additional 143 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Down 7.1 %

NTRA opened at $150.99 on Friday. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The business's 50-day moving average price is $147.51 and its 200-day moving average price is $155.39. The company has a market cap of $20.41 billion, a P/E ratio of -85.79 and a beta of 1.79.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. The firm had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business's quarterly revenue was up 36.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.56) earnings per share. On average, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on NTRA shares. Morgan Stanley boosted their price objective on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Guggenheim boosted their price target on shares of Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, January 17th. Piper Sandler increased their price target on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. BTIG Research reaffirmed a "buy" rating on shares of Natera in a research report on Friday, February 28th. Finally, UBS Group increased their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Natera has a consensus rating of "Moderate Buy" and an average target price of $181.82.

Insider Activity at Natera

In other news, CFO Michael Burkes Brophy sold 792 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $146.04, for a total value of $115,663.68. Following the completion of the transaction, the chief financial officer now owns 71,869 shares of the company's stock, valued at approximately $10,495,748.76. This represents a 1.09 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 87,272 shares of Natera stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total value of $12,514,804.80. Following the sale, the chief executive officer now owns 203,354 shares in the company, valued at $29,160,963.60. This represents a 30.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 152,436 shares of company stock worth $22,019,079 over the last quarter. Corporate insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.